Pepcid AC proposed switch in Canada gets pharmacy-sale recommendation.
This article was originally published in The Tan Sheet
Executive Summary
PEPCID AC SWITCH IN CANADA PROPOSED FOR PHARMACY-SALE STATUS by the newly formed National Drug Scheduling Advisory Committee (NDSAC) on Aug. 30. Once approved by the Canadian government for nonprescription sale, the heartburn remedy will be marketed by Merck Frosst.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning